VERONA PHARMA P/S (VRNA) Scheduled to Post Earnings on Tuesday

VERONA PHARMA P/S (NASDAQ:VRNA) is set to release its earnings data before the market opens on Tuesday, August 6th. Analysts expect VERONA PHARMA P/S to post earnings of ($0.61) per share for the quarter.

VERONA PHARMA P/S (NASDAQ:VRNA) last issued its earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.04. On average, analysts expect VERONA PHARMA P/S to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of VRNA stock traded down $0.12 on Wednesday, reaching $4.20. The stock had a trading volume of 107 shares, compared to its average volume of 3,932. The stock’s 50-day moving average price is $5.03. The stock has a market capitalization of $58.72 million, a price-to-earnings ratio of -2.08 and a beta of -1.00. VERONA PHARMA P/S has a 12 month low of $3.65 and a 12 month high of $14.50.

A number of brokerages have recently issued reports on VRNA. Wedbush dropped their target price on shares of Benefitfocus from $52.00 to $40.00 and set an “outperform” rating on the stock in a report on Monday. Zacks Investment Research raised shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Tuesday, July 16th. Finally, BTIG Research set a $14.00 price target on shares of ARBOR RLTY TR I/SH and gave the company a “buy” rating in a report on Wednesday, April 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. VERONA PHARMA P/S currently has an average rating of “Buy” and a consensus price target of $26.63.

VERONA PHARMA P/S Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.

Further Reading: Quick Ratio

Earnings History for VERONA PHARMA P/S (NASDAQ:VRNA)

Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with's FREE daily email newsletter.